Menu
Search
|

Menu

Close
X

Madrigal Pharmaceuticals Inc MDGL.OQ (NASDAQ Stock Exchange Capital Market)

143.72 USD
-2.51 (-1.72%)
As of 3:59 PM EST
chart
Previous Close 146.23
Open 150.77
Volume 346,641
3m Avg Volume 78,137
Today’s High 150.77
Today’s Low 122.39
52 Week High 325.58
52 Week Low 39.06
Shares Outstanding (mil) 12.50
Market Capitalization (mil) 586.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.456
FY17
-2.541
FY16
-28.235
FY15
-13.038
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
9.52
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
0.00
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
-70.04
14.22
Return on Equity (TTM)
vs sector
-70.04
15.99

EXECUTIVE LEADERSHIP

Paul Friedman
Chairman of the Board, Chief Executive Officer, Since 2016
Salary: $400,000.00
Bonus: $335,000.00
Marc Schneebaum
Chief Financial Officer, Senior Vice President, Since 2014
Salary: $365,000.00
Bonus: $244,500.00
Rebecca Taub
Chief Medical Officer, Executive Vice President - Research & Development and Director, Since 2016
Salary: $370,000.00
Bonus: $247,900.00
Frederick Craves
Lead Independent Director, Since 2016
Salary: --
Bonus: --
Kenneth Bate
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Barr Harbor Dr Ste 400
CONSHOHOCKEN   PA   19428-2978

Phone: +1404.3809263

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

SPONSORED STORIES